Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Mayo Clinic

Neither a doctor nor a teaching hospital

Research payments

$225,424,419

14,017 payments

Through program year 2025, Mayo Clinic is reported as receiving $225,424,419 in research payments, across 14,017 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $46,940,970 2,837
2024 Research $46,075,594 2,146
2023 Research $33,171,273 2,247
2022 Research $31,082,450 2,162
2021 Research $29,377,434 1,681
2020 Research $20,032,233 1,410
2019 Research $18,744,465 1,534

Breakdown

Who paid Research payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $38,926,295 406 payments
  2. GlaxoSmithKline, LLC. $32,984,286 265 payments
  3. Pfizer Inc. $12,098,303 1,054 payments
  4. Edwards Lifesciences Corporation $12,057,177 574 payments
  5. Eli Lilly and Company $10,462,578 140 payments
  6. Amgen Inc. $10,243,672 104 payments
  7. Regeneron Pharmaceuticals, Inc. $6,634,346 682 payments
  8. Janssen Research & Development, LLC $6,543,639 498 payments
  9. Celgene Corporation $5,886,311 82 payments
  10. Novartis Pharmaceuticals Corporation $5,382,537 92 payments
Studies the money was for Research payments · program years 2019–2025
  1. The Burden of Respiratory Syncytial Virus Infection in Adults With Hig $17,356,182 12 payments
  2. A Community-Based Prospective Cohort Study to Assess the Burden of Res $8,347,636 14 payments
  3. MK-3475 pembrolizumab in combination with standard therapy for newly diagnosed glioblastoma $4,871,081 5 payments
  4. The MITRAL II Pivotal Trial: Mitral Implantation of TRAnscatheter vaLves $4,077,995 11 payments
  5. Phase II study of pemetrexed and pembrolizumab in recurrent and,or metastatic salivary gland malignancies $4,037,575 5 payments
  6. STUDY NAME#Effect of sotatercept on central cardiopulmonary performance and peripheral O2 transport during exercise - a comprehensive, paired cardiopulmonary exercise study with partial vasodilator withdrawal $3,457,470 2 payments
  7. Randomized phase 2 study to evaluate a novel drug sequencing strategy of pembrolizumab followed by ramucirumab plus paclitaxel in advanced gastric and gastroesophageal junction GEJ adenocarcinoma $2,621,718 3 payments
  8. STUDY NAME#MC210706 Efficacy and Safety Study of Neoadjuvant Efineptakin alfa NT-I7 and Pembrolizumab in Recurrent Glioblastoma $2,253,946 1 payment
  9. STUDY NAME#MC220601# Folate Receptor alpha Dendritic Cells FR DCs plus Pembrolizumab for Patients with Advanced Stage Ovarian Cancer FRAPPE $2,146,873 1 payment
  10. CLASP II TR Pivotal, Study No. 2019-07 $2,035,726 31 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $2,356,123 200 payments
  2. Patient care $684,608 53 payments
  3. Overhead $133,632 11 payments
  4. Non-patient care $132,240 11 payments
  5. Professional salary support $49,485 3 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record